7.5. Analysis.
Comparison 7 Non‐comparative studies: proportion of participants with non‐serious adverse events, Outcome 5 Musculoskeletal system.
| Musculoskeletal system | ||
|---|---|---|
| Study | Symptom | Adverse events/total number of participants |
| Chest pain | ||
| Arnold 2004 | Chest pain | 0/76 |
| Hammerness 2009 | Chest pain | 2/57 |
| Shang 2015 | Chest pain | 1/66 |
| Height | ||
| Jensen 1999 (MTA) | No difference | ‐ |
| Kim 2010 | Increased from baseline | 128.7 cm (SD = 9.10) |
| Mohammadi 2012a | Increased from baseline | 133.8 cm (SD = 14.81) |
| Vincent 1990 | No difference | 158.7 cm (SD = 10.2) |
| Wiguna 2012 | Increased from baseline | 0.55 cm (SD = no information) |
| Yalcin 2014 | Increased from baseline | 134.6 cm (SD = 12.32) |
| Weight | ||
| Davari‐Ashtiani 2010 | Increased from baseline | Weight gain in 1/16 participants |
| Germinario 2013 | Increased from baseline | 38.4 kg (SD = 11.3) |
| Kim 2010 | No difference | 28.5 kg (SD = 6.40) |
| Kratochvil 2002 | No difference | 40.7 kg (SD = 17.2) |
| Mohammadi 2012a | Increased from baseline | 32.7 kg (SD = 14.7) |
| Vincent 1990 | No difference | Observed weight: 47.9 kg (SD = 10.3) Expected weight: 48.1 kg (SD = 10.6) |
| Wiguna 2012 | Decreased from baseline | 36.2 kg (SD = 11.9) |
| Yalcin 2014 | Increased from baseline | Weight gain in 15/33 participants |
| BMI | ||
| Gerwe 2009 | No difference | Mean change from baseline: −0.3 kg/m2 (SD = 0.70) |
| Mohammadi 2012a | No difference | 18.2 kg/m2 (SD = 4.74) |
| Yalcin 2014 | No difference | Methylphenidate group: 18.1 kg/m2 (SD = 2.76) Untreated group: 17.8k kg/m2 (SD = 2.71) |
| Height z score | ||
| Bereket 2005 | Decreased from baseline | ‐ |
| Germinario 2013 | Decreased from baseline | Z score = 0.36 (SD = 1.21) |
| Moungnoi 2011 | Decreased from baseline | Z score = 0.09 (SD = no information) |
| Poulton 2003 | Decreased from baseline | Z score = 0.26 (SD = 0.82) |
| Poulton 2012 | Decreased from baseline | Z score = 0.34 (SD = 0.81) |
| Schertz 1996 | Decreased from baseline | Z score = ‐0.1(SD = no information) |
| Spencer 1992 | Decreased from baseline | Z score = ‐0.23 (SD = 0.42) |
| Weight z score | ||
| Bereket 2005 | Decreased from baseline | 0.2 (SD = 1.04) |
| Gerwe 2009 | Decreased from baseline | 0.26 kg (SD = 1.40) |
| Moungnoi 2011 | Decreased from baseline | Z score = 0.01 (SD = no information) |
| Poulton 2003 | Decreased from baseline | Z score = 0.44 (SD = 0.97) |
| Schertz 1996 | Decreased from baseline | ‐ |
| BMI z score | ||
| Bereket 2005 | No difference | After 14 months: Age‐adjusted SD = 0.71 Sex‐adjusted SD = 0.65 |
| Dubnov‐Raz 2011 | No difference | ‐ |
| Poulton 2012 | No difference | ‐ |
| Increased mobility | ||
| Ardic 2014 | Increased mobility | 22/122 |
| Bone mineral density | ||
| Lahat 2000 | Quote: "There was no significant difference between serum calcium, phosphorus or bone‐specific alkaline phosphatase, urinary deoxypyridinoline, or bone mineral density in the two groups of children. No child deviated from his height percentile during the treatment period." | NA |